147438-30-0.: Everolimus Related Compound 3
Everolimus Related Compound 3 (CAS No: 147438-30-0) or (S)-1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxotrideca-3,5,7-trien-1-yl)-2-hydroxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetyl)piperidine-2-carboxylic acid.Everolimus is an inhibitor of mTOR. which is used in management of neuroendocrine tumors.
Additional information on CAS 147438-30-0.
VE008144
147438-30-0.
C32H49NO9
591.74 g/mol
Everolimus
(S)-1-(2-((2R, 3R, 6S)-6-((2S, 3E, 5E, 7E, 9S, 11R)-2, 13-dimethoxy-3, 9, 11-trimethyl-12-oxotrideca-3, 5, 7-trien-1-yl)-2-hydroxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetyl)piperidine-2-carboxylic acid
N/A
Sci-Hub, Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opinion on Pharmacotherapy, 19(8), 909–928, 10.1080/14656566.2018.1476492. (2018). Sci-Hub.se. https://sci-hub.se/10.1080/14656566.2018.1476492
In-stock
Other products related to everolimus
Name of Impurity | Catalogue No. | |
---|---|---|
Everolimus CCSB Impurity B | VE009237 | View |
Everolimus EP Impurity A | VE008423 | View CAS 53123-88-9 |
Everolimus EP Impurity B | VE008464 | View CAS 1062122-63-7 |
Everolimus EP Impurity C | VL2280001 | View |
Everolimus EP Impurity D | VE008497 | View |
Everolimus EP Impurity E | VE009863 | View CAS 1237826-25-3 |
Everolimus EP Impurity F | VE009874 | View |
Everolimus IP Impurity E | VL2280003 | View CAS 147438-30-0 |
Everolimus Inhouse Impurity D | VL2280002 | View |
Everolimus tert-Butyldimethylsilyl Ether Impurity | VL2280004 | View CAS 159351-68-5 |
O-Desmethyl Everolimus | VE008975 | View CAS 745779-75-3 |